APA
Van Laethem J., Riess H., Jassem J., Haas M., Martens U. M., Weekes C., Peeters M., Ross P., Bridgewater J., Melichar B., Cascinu S., Saramak P., Michl P., Van Brummelen D., Zaniboni A., Schmiegel W., Dueland S., Giurescu M., Garosi V. L., Roth K., Schulz A., Seidel H., Rajagopalan P., Teufel M. & Childs B. H. (20171031). Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer. : Targeted oncology.
Chicago
Van Laethem Jean-Luc, Riess Hanno, Jassem Jacek, Haas Michael, Martens Uwe M, Weekes Colin, Peeters Marc, Ross Paul, Bridgewater John, Melichar Bohuslav, Cascinu Stefano, Saramak Piotr, Michl Patrick, Van Brummelen David, Zaniboni Alberto, Schmiegel Wollf, Dueland Svein, Giurescu Marius, Garosi Vittorio L, Roth Katrin, Schulz Anke, Seidel Henrik, Rajagopalan Prabhu, Teufel Michael and Childs Barrett H. 20171031. Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer. : Targeted oncology.
Harvard
Van Laethem J., Riess H., Jassem J., Haas M., Martens U. M., Weekes C., Peeters M., Ross P., Bridgewater J., Melichar B., Cascinu S., Saramak P., Michl P., Van Brummelen D., Zaniboni A., Schmiegel W., Dueland S., Giurescu M., Garosi V. L., Roth K., Schulz A., Seidel H., Rajagopalan P., Teufel M. and Childs B. H. (20171031). Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer. : Targeted oncology.
MLA
Van Laethem Jean-Luc, Riess Hanno, Jassem Jacek, Haas Michael, Martens Uwe M, Weekes Colin, Peeters Marc, Ross Paul, Bridgewater John, Melichar Bohuslav, Cascinu Stefano, Saramak Piotr, Michl Patrick, Van Brummelen David, Zaniboni Alberto, Schmiegel Wollf, Dueland Svein, Giurescu Marius, Garosi Vittorio L, Roth Katrin, Schulz Anke, Seidel Henrik, Rajagopalan Prabhu, Teufel Michael and Childs Barrett H. Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer. : Targeted oncology. 20171031.